TNFRSF17 and amyotrophic lateral sclerosis: Finally, to investigate if ALS-BCMA responses reflect dmLT adjuvanticity, we compared magnitudes of ALS-BCMA responses in subjects who received two priming doses of ETVAX (n = 21) with individuals who received ETVAX plus 10 μg dmLT (n = 24).